Atezolizumab vs Durvalumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
Atezolizumab
Marketed by Roche and partners
NCT02008227 · Phase 3 · completed
This large randomized, active-controlled Phase 3 trial (1225 patients) compared atezolizumab to docetaxel in advanced NSCLC. The primary endpoint was overall survival, a hard clinical endpoint, and it was met: median OS 13.8 months for atezolizumab vs 9.6 months for docetaxel, HR 0.73 (95% CI 0.62-0.87), p=0.0003. The trial was not blinded (open-label), so despite the robust randomized design and positive result, the evidence is graded moderate rather than strong.
Next expected readout: November 2026 · NCT04958811 (registry estimate)
Reported efficacy
Independent Review Facility (IRF)-Assessed Event Free Survival (EFS) (Up to approximately 96 months): IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 (missed)
Result source: NCT03456063
Durvalumab
Marketed by AstraZeneca and partners
NCT02125461 · Phase 3 · completed
Patients were randomly assigned in a 2:1 ratio and quadruple-blinded to durvalumab or matching placebo, with 476 receiving durvalumab and 237 placebo. The prespecified primary clinical endpoints were met: progression-free survival was 16.8 versus 5.6 months (HR 0.52, p<0.0001), and overall survival also favored durvalumab (HR 0.68, p=0.00251).
Next expected readout: December 2026 · NCT05000710 (registry estimate)
Reported efficacy
Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.); Overall Survival (From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.): Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8) (met)
Result source: NCT02125461
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Atezolizumab
- 7 vs 5.5vs Nab-Paclitaxel+CarboplatinNCT02367781
40 other results
- 19.4 vs 16.6 NCT04513925
- 14.2 vs 13.8 NCT04513925
- 6.5 vs 5.6 NCT02367794
- 5.6 vs 5.6 NCT02367794
- 8.3 vs 9.9 NCT04619797
- 7.7 NCT02657434
- 2.8 vs 2.9 NCT03735121
- 2.8 vs 4 NCT02008227
- 2.8 vs 4.1 NCT02008227
- 2.7 vs 3.8 NCT02008227
- 8.1 vs 5 NCT02409342
- 19.4 vs 18.5 NCT04513925
- 16.7 vs 13.8 NCT04513925
- 4.6 vs 4 NCT04471428
- 4.2 vs 4 NCT03191786
- 4.2 vs 3 NCT03191786
- 8.4 vs 5.6 NCT02367794
- 7 vs 5.6 NCT02367794
- 7.1 vs 5.6 NCT02367794
- 7 vs 5.6 NCT02367794
- 9.8 vs 12.0 NCT04619797
- 11.8 vs 14.1 NCT04619797
- 6.5 NCT02367794
- 5.6 NCT02367794
- 7.3 vs 7.2 NCT04042558
- 2.7 vs 3.4 NCT01903993
- 1.7 vs 1.5 NCT03023423
- 2.7 NCT03285763
- 3.7 NCT03285763
- 4.1 NCT02848651
- 4.2 NCT01903993
- 2.7 NCT01846416
- 3.7 NCT01846416
- 2.8 NCT04426825
- 2.8 NCT04426825
- 26.1 NCT03102242
- 4.5 NCT01846416
- 2.5 NCT01846416
- 5.5 NCT01846416
- 4.3 NCT01846416
- Durvalumab
- 16.8 vs 5.6+11.2 vs placeboNCT02125461
24 other results
- 13.8 vs 9.4 NCT03519971
- 16.7 vs 15.6 NCT04026412
- 3.8 vs 3.5 NCT02352948
- 3.5 vs 3.5 NCT02352948
- 6.2 vs 5.5 NCT03164616
- 16.8 vs 15.7 NCT04026412
- 17.4 vs 15.7 NCT04026412
- 16.8 vs 16.5 NCT04026412
- 17.7 vs 16.5 NCT04026412
- 3.5 NCT02352948
- 3.1 NCT02352948
- 21.1 vs 7.3 NCT03822351
- 19.8 vs 7.3 NCT03822351
- 10.3 NCT04249362
- 7.6 NCT04249362
- 13.1 NCT03693300
- 3 NCT02879617
- 2 NCT03164772
- 1.8 NCT03164772
- 2 NCT03164772
- 1.8 NCT03164772
- 20.4 NCT03801902
- 30.2 NCT03801902
- 3.7 NCT03693300
OS, median
- Atezolizumab
- 13.8 vs 9.6vs DocetaxelNCT02008227
36 other results
- 15.7 vs 10.3 NCT02008227
- 13.3 vs 9.8 NCT02008227
- 14.3 vs 10.8 NCT02008227
- 16.6 vs 11.4 NCT02008227
- 19.2 vs 14.7 NCT02366143
- 19 vs 14.7 NCT02366143
- 18.6 vs 13.9 NCT02367781
- 14.2 vs 13.5 NCT02367794
- 12.6 vs 13.5 NCT02367794
- 20.5 vs 9.7 NCT02008227
- 20.2 vs 13.1 NCT02409342
- 10.7 vs 10.5 NCT04471428
- 10.3 vs 9.2 NCT03191786
- 18.9 vs 23.1 NCT04619797
- 17.5 NCT02657434
- 10.9 vs 10.1 NCT03735121
- 17 vs 13.5 NCT02367781
- 45.6 vs 45.8 NCT04513925
- 9.4 vs 10.3 NCT03191786
- 20.4 vs 14.5 NCT02367794
- 14.8 vs 14.5 NCT02367794
- 14.8 vs 15 NCT02367794
- 14.9 vs 15 NCT02367794
- 20.7 vs 33.6 NCT04619797
- 23.8 vs 33.6 NCT04619797
- 14.2 NCT02367794
- 12.6 NCT02367794
- 12.6 vs 9.7 NCT01903993
- 17.2 vs 16.8 NCT04042558
- 7.1 NCT03023423
- 11.2 NCT03285763
- 14.8 NCT02848651
- 9.3 NCT01846416
- 14.1 NCT04426825
- 14.4 NCT01846416
- 6.8 NCT01846416
- Durvalumab
- 11.7 vs 8.7vs SoCNCT02352948
20 other results
- 11.5 vs 8.7 NCT02352948
- 36.4 vs 29.5 NCT03519971
- 14 vs 13.3 NCT03164616
- 34.6 vs 39.8 NCT04026412
- 39.5 vs 39.8 NCT04026412
- 11.5 NCT02352948
- 10 NCT02352948
- 6 NCT02879617
- 13.3 NCT02087423
- 10.9 NCT02087423
- 9.3 NCT02087423
- 39 NCT03693300
- 9.9 NCT02087423
- 13.2 NCT02087423
- 21.1 NCT04249362
- 16.8 NCT04249362
- 7.5 NCT03164772
- 16.0 NCT04003246
- 23.5 NCT03164772
- 12.3 NCT03693300
ORR
- Atezolizumab
- 11% vs 10.5%vs Atezolizumab IVNCT03735121
30 other results
- 13.6% vs 13.4% NCT02008227
- 17.8% vs 16.2% NCT02008227
- 13.7% vs 11.8% NCT02008227
- 60.2% vs 41% NCT02367781
- 33.9% vs 34.6% NCT04513925
- 49.7% vs 41% NCT02367794
- 38.3% vs 28.6% NCT02409342
- 45.5% vs 47.5% NCT04513925
- 37% vs 37.2% NCT04513925
- 40.9% vs 39.5% NCT04513925
- 11.8% vs 13.3% NCT04471428
- 16.9% vs 7.9% NCT03191786
- 49.3% vs 41% NCT02367794
- 50.2% vs 56.6% NCT04619797
- 51.7% NCT02657434
- 4.3% vs 13% NCT03023423
- 0% vs 7.9% NCT03977467
- 17.1% NCT02848651
- 21% NCT01846416
- 18.2% NCT04426825
- 32% NCT01846416
- 23% NCT01846416
- 15.3% vs 14.7% NCT01903993
- 11.5% NCT03285763
- 12.4% NCT03285763
- 16.7% NCT01903993
- 19% NCT01846416
- 17.4% NCT04426825
- 29% NCT01846416
- 23% NCT01846416
- Durvalumab
- 60.7% vs 60.6%+0.1 vs placeboNCT03519971
10 other results
- 35.5% vs 6.8% NCT02352948
- 14.9% vs 6.8% NCT02352948
- 15.4% vs 6.8% NCT02352948
- 67.6% vs 64.5% NCT04026412
- 72.2% vs 64.5% NCT04026412
- 61.3% vs 57.9% NCT04026412
- 63.1% vs 57.9% NCT04026412
- 35% vs 23.9% NCT03822351
- 40.3% vs 23.9% NCT03822351
- 58.1% NCT02572843
Duration of response, median
- Atezolizumab
- 16.3 vs 6.2vs DocetaxelNCT02008227
33 other results
- 16 vs 6.2 NCT02008227
- 23.9 vs 6.3 NCT02008227
- 15.1 vs 11.2 NCT03735121
- 43.6 vs 28.1 NCT04513925
- 36.2 vs 30.2 NCT04513925
- 36.4 vs 32.4 NCT04513925
- 35.3 vs 30.2 NCT04513925
- 7.2 vs 5.2 NCT02367794
- 7 vs 5.2 NCT02367794
- 9.4 vs 11.1 NCT04619797
- 5.5 vs 4.3 NCT04471428
- 14 vs 7.8 NCT03191786
- 9.5 NCT02657434
- 6.3 vs 4.6 NCT04042558
- 18.6 vs 7.2 NCT01903993
- 2.9 vs 5.8 NCT03023423
- 16.6 NCT03285763
- 20.5 NCT03285763
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 0.0 NCT02031458
- 16.3 NCT02848651
- 14.9 NCT01903993
- 17 NCT01846416
- 6.4 NCT04426825
- 6.4 NCT04426825
- 9.2 NCT01846416
- Durvalumab
- 30.7 vs 18.6+12.1 vs placeboNCT03519971
17 other results
- 9.5 vs 10.8 NCT02352948
- 12.2 vs 10.8 NCT02352948
- 10 vs 10.8 NCT02352948
- 7.4 vs 6 NCT03164616
- 25.8 vs 25.2 NCT04026412
- 31.8 vs 25.2 NCT04026412
- 22.8 vs 27.9 NCT04026412
- 33.2 vs 27.9 NCT04026412
- 29.9 NCT03822351
- 23 NCT03822351
- 12.3 NCT02087423
- 13.1 NCT04249362
- 7.9 NCT04249362
- 9.9 NCT03164772
- 5.8 NCT03164772
- 9.9 NCT03164772
- 5.8 NCT03164772
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety
Coverage. Atezolizumab: 17 of 17 rows · Durvalumab: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Atezolizumab Rows use multiple source trials | Durvalumab Rows use multiple source trials |
|---|---|---|
| Disease Control responder rate · % of participants | 100% (n=1) vs 50% (n=4) Atezolizumaba,b,c NCT03977467 · Phase 2 · registry result, not featured evidence · combination | 65.8% (n=219) vs 65.1% (n=109) placebo @ 24wka,b,c NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 2 other source trials80% (n=60) vs 58.2% (n=67) Durvalumab Monotherapy NCT03822351 · Phase 2 · registry result, not featured evidence · combination 79% (n=62) vs 58.2% (n=67) Durvalumab Monotherapy NCT03822351 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | 16.6 monthsd,e,f,g,c NCT03285763 · Phase 4 · registry result, not featured evidence show 1 more dose20.5 months NCT03285763 · Phase 4 · registry result, not featured evidence | 12.3 monthse,f,g,c NCT02087423 · Phase 2 · registry result, not featured evidence · combination 7 other source trials13.13 months* NCT04249362 · Phase 2 · registry result, not featured evidence · converted to months from 56.9 weeks as posted 7.87 months* NCT04249362 · Phase 2 · registry result, not featured evidence · converted to months from 34.1 weeks as posted NA months NCT03693300 · Phase 2 · registry result, not featured evidence 9.95 months* NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 43.1 weeks as posted 9.95 months* NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 43.1 weeks as posted 5.79 months* NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 25.1 weeks as posted 5.79 months* NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 25.1 weeks as posted |
| Major Pathologic responder rate · % of participants No placebo or comparator arm | 65.4% (n=26) @ 12wk*f,h NCT02716038 · Phase 2 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted | 11.1% (n=27) @ 6wk1500 mgd,f,h NCT03794544 · Phase 2 · registry result, not featured evidence show 3 more doses31.3% (n=16) @ 6wk1500 mg + 200 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 30% (n=20) @ 6wk1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 19% (n=21) @ 6wk1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination |
| ORR responder rate · % of participants No placebo or comparator arm | 11.5% (n=615)d,e,f,g,c NCT03285763 · Phase 4 · registry result, not featured evidence show 1 more dose12.4% (n=615) NCT03285763 · Phase 4 · registry result, not featured evidence | 58.1% (n=62)e,f,g,c NCT02572843 · Phase 2 · registry result, not featured evidence |
| OS Rate at 12 responder rate · % of participants | 45.49% (n=107) vs 24.79% (n=98) Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) @ 104wkf,g NCT02409342 · Phase 3 | 58.4% (n=219) vs 59.5% (n=109) placebo @ 104wkf,g NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Overall Survival time to event · months No placebo or comparator arm | 11.2 monthsi,f,c NCT03285763 · Phase 4 · registry result, not featured evidence 9 other source trials17.5 months NCT02657434 · Phase 3 · registry result, not featured evidence · combination 12.6 months NCT02367794 · Phase 3 · registry result, not featured evidence · combination 14.2 months NCT02367794 · Phase 3 · registry result, not featured evidence · combination 14.06 months NCT04426825 · Phase 2 · registry result, not featured evidence · combination NA months NCT03102242 · Phase 2 · registry result, not featured evidence 14.82 months NCT02848651 · Phase 2 · registry result, not featured evidence 14.4 months NCT01846416 · Phase 2 · registry result, not featured evidence 6.8 months NCT01846416 · Phase 2 · registry result, not featured evidence · combination 9.3 months NCT01846416 · Phase 2 · registry result, not featured evidence · combination | 10 monthsd,i,f,c NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 1 more dose11.5 months NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Overall Survival Rate at 12 absolute value · percentage points No placebo or comparator arm | 86.8% (n=38) @ 52wkf,g NCT04776447 · Phase 2 · registry result, not featured evidence · combination | 64% (n=53) @ 52wkd,f,g NCT04249362 · Phase 2 · registry result, not featured evidence show 1 more dose65.5% (n=49) @ 52wk NCT04249362 · Phase 2 · registry result, not featured evidence |
| PFS time to event · months No placebo or comparator arm | 2.7 monthsd,i,f,c NCT03285763 · Phase 4 · registry result, not featured evidence show 1 more dose3.7 months NCT03285763 · Phase 4 · registry result, not featured evidence | 3.1 monthsd,i,f,c NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 1 more dose3.5 months NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| PFS-12 absolute value · months No placebo or comparator arm | 4.64 months @ 52wkf,g NCT04426825 · Phase 2 · registry result, not featured evidence · combination | 6.83 months @ 52wk*f,g NCT04003246 · Phase 2 · registry result, not featured evidence · converted to months from 208 days as posted |
| PFS12 absolute value · percentage points No placebo or comparator arm | 68.4% (n=38) @ 52wkf,g NCT04776447 · Phase 2 · registry result, not featured evidence · combination | 46.8% (n=53) @ 52wkd,f,g NCT04249362 · Phase 2 · registry result, not featured evidence show 1 more dose31.8% (n=49) @ 52wk NCT04249362 · Phase 2 · registry result, not featured evidence |
| Progressive Disease event count · % of participants No placebo or comparator arm progressive disease (PD) | 7.9% (n=38)*f,g,c progressive disease (PD) NCT04776447 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted | 26% (n=38)f,g,c Progressive Disease (PD) NCT02879617 · Phase 2 · registry result, not featured evidence |
| Stable Disease event count · % of participants No placebo or comparator arm Stable disease (SD) | 18.4% (n=38)*f,g,c Stable disease (SD) NCT04776447 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted | |
| Time to Response time to event · months No placebo or comparator arm | 1.577 monthsf,c NCT04426825 · Phase 2 · registry result, not featured evidence · combination | 2.1 monthsd,f,c NCT02087423 · Phase 2 · registry result, not featured evidence · combination show 1 more dose1.9 months NCT02087423 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | n/a: no completion milestonej NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 37 more results—Arm A (Atezo+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT02409342 · Phase 3 n/a: no completion milestone NCT02367781 · Phase 3 · combination 97.9% NCT03285763 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT04513925 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT04471428 · Phase 3 · registry result, not featured evidence · combination 100%1875 mg NCT03735121 · Phase 3 · registry result, not featured evidence 38.5%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 66.7%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 53.3%1200 mg NCT03735121 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT03191786 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02657434 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm A: Atezolizumab + Paclitaxel + NCT02367794 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm B: Atezolizumab + Nab-Paclitax NCT02367794 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination 15.8% NCT04776447 · Phase 2 · registry result, not featured evidence · combination 5.6% NCT04042558 · Phase 2 · registry result, not featured evidence —Continuation Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence —Crossover Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT03977467 · Phase 2 · registry result, not featured evidence · combination 36.5% NCT02927301 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT04426825 · Phase 2 · registry result, not featured evidence · combination 16.1% NCT02716038 · Phase 2 · registry result, not featured evidence · combination 3.1% NCT03102242 · Phase 2 · registry result, not featured evidence 0% NCT03526900 · Phase 2 · registry result, not featured evidence 69.3% NCT02848651 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort 1: First Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort 2: Second Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort 3: Third Line and Beyond At NCT02031458 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT01903993 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneAtezolizumab (MPDL3280) : 1L Parti NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 1L Part NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 2L+ Bra NCT01846416 · Phase 2 · registry result, not featured evidence · combination —Atezolizumab (MPDL3280A) : 2L+ Par NCT01846416 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneRandomized Phase: Daratumumab + At NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestoneSafety Run-in Phase: Daratumumab + NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination | 62.6%k NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 34 more results79%Sub-study A: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 75.2%Sub-study B: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 74.1%Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 76.3% NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 31% NCT04416633 · Phase 4 · registry result, not featured evidence 64.1%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 100% NCT04642469 · Phase 3 · registry result, not featured evidence 26.7% NCT04385368 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 1 (EGFR/ALK+) NCT02087423 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 2 NCT02087423 · Phase 2 · registry result, not featured evidence —Cohort 3 (TC >=90%) NCT02087423 · Phase 2 · registry result, not featured evidence 0%Durvalumab Cohort A: Standard Radi NCT04249362 · Phase 2 · registry result, not featured evidence 0%Durvaumab Cohort B: Palliative Rad NCT04249362 · Phase 2 · registry result, not featured evidence 90% NCT04003246 · Phase 2 · registry result, not featured evidence 1.5% NCT02572843 · Phase 2 · registry result, not featured evidence 51.7%Arm A (Durvalumab + Oleclumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination 51.6%Arm B (Durvalumab + Monalizumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Monalizumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Oleclumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab ECOG PS 0 or 1 NCT03693300 · Phase 2 · registry result, not featured evidence 66.7%Durvalumab ECOG PS 2 NCT03693300 · Phase 2 · registry result, not featured evidence 13.3%Arm 1 (Durvalumab Monotherapy) NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy 13.3%Arm 2 (Durvalumab Plus SBRT) NCT02904954 · Phase 2 · registry result, not featured evidence · combination 0% NCT02879617 · Phase 2 · registry result, not featured evidence 3.7%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 6.3%1500 mg + 200 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 5%1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 14.3%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 78.3%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 91.2%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 7.1%Arm I (CLOSED) (Durvalumab and ACR NCT03801902 · Phase 1 · registry result, not featured evidence 0%Arm II (CLOSED) (Durvalumab and St NCT03801902 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —j NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 37 more results—Arm A (Atezo+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 — NCT02409342 · Phase 3 — NCT02367781 · Phase 3 · combination — NCT03285763 · Phase 4 · registry result, not featured evidence — NCT04513925 · Phase 3 · registry result, not featured evidence · combination — NCT04471428 · Phase 3 · registry result, not featured evidence · combination —1875 mg NCT03735121 · Phase 3 · registry result, not featured evidence —1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence —1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence —1200 mg NCT03735121 · Phase 3 · registry result, not featured evidence — NCT03191786 · Phase 3 · registry result, not featured evidence — NCT02657434 · Phase 3 · registry result, not featured evidence · combination 0.6%Arm A: Atezolizumab + Paclitaxel + NCT02367794 · Phase 3 · registry result, not featured evidence · combination 0%Arm B: Atezolizumab + Nab-Paclitax NCT02367794 · Phase 3 · registry result, not featured evidence · combination — NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination — NCT04776447 · Phase 2 · registry result, not featured evidence · combination — NCT04042558 · Phase 2 · registry result, not featured evidence —Continuation Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence —Crossover Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence 0% NCT03977467 · Phase 2 · registry result, not featured evidence · combination — NCT02927301 · Phase 2 · registry result, not featured evidence — NCT04426825 · Phase 2 · registry result, not featured evidence · combination — NCT02716038 · Phase 2 · registry result, not featured evidence · combination 3.1% NCT03102242 · Phase 2 · registry result, not featured evidence — NCT03526900 · Phase 2 · registry result, not featured evidence — NCT02848651 · Phase 2 · registry result, not featured evidence —Cohort 1: First Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence —Cohort 2: Second Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence —Cohort 3: Third Line and Beyond At NCT02031458 · Phase 2 · registry result, not featured evidence — NCT01903993 · Phase 2 · registry result, not featured evidence 9.7%Atezolizumab (MPDL3280) : 1L Parti NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 1L Part NCT01846416 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280A) : 2L+ Bra NCT01846416 · Phase 2 · registry result, not featured evidence · combination —Atezolizumab (MPDL3280A) : 2L+ Par NCT01846416 · Phase 2 · registry result, not featured evidence · combination —Randomized Phase: Daratumumab + At NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination —Safety Run-in Phase: Daratumumab + NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination | —k NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 34 more results—Sub-study A: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Sub-study B: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 — NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 — NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 6% NCT04416633 · Phase 4 · registry result, not featured evidence —Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination —Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination — NCT04642469 · Phase 3 · registry result, not featured evidence — NCT04385368 · Phase 3 · registry result, not featured evidence · combination —Cohort 1 (EGFR/ALK+) NCT02087423 · Phase 2 · registry result, not featured evidence · combination —Cohort 2 NCT02087423 · Phase 2 · registry result, not featured evidence —Cohort 3 (TC >=90%) NCT02087423 · Phase 2 · registry result, not featured evidence —Durvalumab Cohort A: Standard Radi NCT04249362 · Phase 2 · registry result, not featured evidence —Durvaumab Cohort B: Palliative Rad NCT04249362 · Phase 2 · registry result, not featured evidence — NCT04003246 · Phase 2 · registry result, not featured evidence — NCT02572843 · Phase 2 · registry result, not featured evidence —Arm A (Durvalumab + Oleclumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Arm B (Durvalumab + Monalizumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Monalizumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Oleclumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab ECOG PS 0 or 1 NCT03693300 · Phase 2 · registry result, not featured evidence —Durvalumab ECOG PS 2 NCT03693300 · Phase 2 · registry result, not featured evidence —Arm 1 (Durvalumab Monotherapy) NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy —Arm 2 (Durvalumab Plus SBRT) NCT02904954 · Phase 2 · registry result, not featured evidence · combination — NCT02879617 · Phase 2 · registry result, not featured evidence —1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence —1500 mg + 200 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination —1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination —1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 4.3%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 11.8%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination —Arm I (CLOSED) (Durvalumab and ACR NCT03801902 · Phase 1 · registry result, not featured evidence —Arm II (CLOSED) (Durvalumab and St NCT03801902 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 32.8%j NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 37 more results42.5%Arm A (Atezo+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 48.3%Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 33.9% NCT02409342 · Phase 3 53.3% NCT02367781 · Phase 3 · combination 32.2% NCT03285763 · Phase 4 · registry result, not featured evidence 32.9% NCT04513925 · Phase 3 · registry result, not featured evidence · combination 41.1% NCT04471428 · Phase 3 · registry result, not featured evidence · combination 20.2%1875 mg NCT03735121 · Phase 3 · registry result, not featured evidence 15.4%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 20.5%1800 mg NCT03735121 · Phase 3 · registry result, not featured evidence 26.7%1200 mg NCT03735121 · Phase 3 · registry result, not featured evidence 49% NCT03191786 · Phase 3 · registry result, not featured evidence 51.2% NCT02657434 · Phase 3 · registry result, not featured evidence · combination 45.5%Arm A: Atezolizumab + Paclitaxel + NCT02367794 · Phase 3 · registry result, not featured evidence · combination 50.3%Arm B: Atezolizumab + Nab-Paclitax NCT02367794 · Phase 3 · registry result, not featured evidence · combination 55.1% NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination 55.3% NCT04776447 · Phase 2 · registry result, not featured evidence · combination 48.5% NCT04042558 · Phase 2 · registry result, not featured evidence 13.5%Continuation Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence 8.4%Crossover Atezolizumab SC NCT05171777 · Phase 2 · registry result, not featured evidence 100% NCT03977467 · Phase 2 · registry result, not featured evidence · combination 34.8% NCT02927301 · Phase 2 · registry result, not featured evidence 17.4% NCT04426825 · Phase 2 · registry result, not featured evidence · combination 10% NCT02716038 · Phase 2 · registry result, not featured evidence · combination 53.1% NCT03102242 · Phase 2 · registry result, not featured evidence 17.5% NCT03526900 · Phase 2 · registry result, not featured evidence 53.3% NCT02848651 · Phase 2 · registry result, not featured evidence 34.1%Cohort 1: First Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence 43.5%Cohort 2: Second Line Atezolizumab NCT02031458 · Phase 2 · registry result, not featured evidence 44.8%Cohort 3: Third Line and Beyond At NCT02031458 · Phase 2 · registry result, not featured evidence 37.3% NCT01903993 · Phase 2 · registry result, not featured evidence —Atezolizumab (MPDL3280) : 1L Parti NCT01846416 · Phase 2 · registry result, not featured evidence 54.8%Atezolizumab (MPDL3280A) : 1L Part NCT01846416 · Phase 2 · registry result, not featured evidence 46.2%Atezolizumab (MPDL3280A) : 2L+ Bra NCT01846416 · Phase 2 · registry result, not featured evidence · combination 49.5%Atezolizumab (MPDL3280A) : 2L+ Par NCT01846416 · Phase 2 · registry result, not featured evidence · combination 47.7%Randomized Phase: Daratumumab + At NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination 57.1%Safety Run-in Phase: Daratumumab + NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination | 29.1%k NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 34 more results37.1%Sub-study A: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 30.8%Sub-study B: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 37.6%Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 47% NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 44.2% NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 21% NCT04416633 · Phase 4 · registry result, not featured evidence 63.8%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 7.1% NCT04642469 · Phase 3 · registry result, not featured evidence 31.1% NCT04385368 · Phase 3 · registry result, not featured evidence · combination 16.2%Cohort 1 (EGFR/ALK+) NCT02087423 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort 2 NCT02087423 · Phase 2 · registry result, not featured evidence 35.3%Cohort 3 (TC >=90%) NCT02087423 · Phase 2 · registry result, not featured evidence 43.4%Durvalumab Cohort A: Standard Radi NCT04249362 · Phase 2 · registry result, not featured evidence 36.7%Durvaumab Cohort B: Palliative Rad NCT04249362 · Phase 2 · registry result, not featured evidence 70% NCT04003246 · Phase 2 · registry result, not featured evidence 53.7% NCT02572843 · Phase 2 · registry result, not featured evidence —Arm A (Durvalumab + Oleclumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Arm B (Durvalumab + Monalizumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination 27.9%Durvalumab + Monalizumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination 33.9%Durvalumab + Oleclumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination 28.1%Durvalumab ECOG PS 0 or 1 NCT03693300 · Phase 2 · registry result, not featured evidence 0%Durvalumab ECOG PS 2 NCT03693300 · Phase 2 · registry result, not featured evidence 40%Arm 1 (Durvalumab Monotherapy) NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy 50%Arm 2 (Durvalumab Plus SBRT) NCT02904954 · Phase 2 · registry result, not featured evidence · combination 55.3% NCT02879617 · Phase 2 · registry result, not featured evidence 11.5%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 31.3%1500 mg + 200 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 5%1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 9.5%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 60.9%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 64.7%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 46.2%Arm I (CLOSED) (Durvalumab and ACR NCT03801902 · Phase 1 · registry result, not featured evidence 41.7%Arm II (CLOSED) (Durvalumab and St NCT03801902 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | j fatigue 27.1% decreased appetite 24.6% cough 24% NCT02008227 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 36 more resultsalopecia 45% anaemia 36.5% nausea 32.5% NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 alopecia 47.8% nausea 37.9% fatigue 34.9% NCT02366143 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 cough 17.4% decreased appetite 16.9% fatigue 16.3% NCT03285763 · Phase 4 · registry result, not featured evidence pruritus 22.6% rash 20.9% cough 19.7% NCT04513925 · Phase 3 · registry result, not featured evidence · combination diarrhoea 44.9% decreased appetite 31.9% nausea 25.4% NCT04471428 · Phase 3 · registry result, not featured evidence · combination 1875 mg anaemia 19% cough 13.4% decreased appetite 12.6% NCT03735121 · Phase 3 · registry result, not featured evidence 1800 mg asthenia 38.5% cough 38.5% diarrhoea 30.8% NCT03735121 · Phase 3 · registry result, not featured evidence 1800 mg anaemia 33.3% fatigue 28.2% nausea 23.1% NCT03735121 · Phase 3 · registry result, not featured evidence 1200 mg anaemia 33.3% asthenia 20% blood cholesterol increased 20% NCT03735121 · Phase 3 · registry result, not featured evidence decreased appetite 22% cough 19.7% fatigue 19.3% NCT03191786 · Phase 3 · registry result, not featured evidence anaemia 44.3% nausea 38.5% constipation 31.6% NCT02657434 · Phase 3 · registry result, not featured evidence · combination anaemia 39.5% alopecia 39.2% fatigue 29.2% NCT02367794 · Phase 3 · registry result, not featured evidence · combination anaemia 56.3% nausea 39.2% neutropenia 36.2% NCT02367794 · Phase 3 · registry result, not featured evidence · combination anaemia 52.8% nausea 39.7% constipation 33.3% NCT04619797 · Phase 2/3 · registry result, not featured evidence · combination neutrophil count decreased 26.3% anemia 15.8% febrile neutropenia 13.2% NCT04776447 · Phase 2 · registry result, not featured evidence · combination injection site reaction 10.3% diarrhoea 6.5% asthenia 5.2% NCT05171777 · Phase 2 · registry result, not featured evidence atrial flutter 100% dry mouth 100% dysplastic naevus 100% NCT03977467 · Phase 2 · registry result, not featured evidence · combination fatigue 43.6% procedural pain 29.8% dyspnoea 22.7% NCT02927301 · Phase 2 · registry result, not featured evidence proteinuria 30.4% aspartate aminotransferase increased 26.1% fatigue 26.1% NCT04426825 · Phase 2 · registry result, not featured evidence · combination neutropenia 50% alanine aminotransferase increased 6.7% aspartate aminotransferase increased 6.7% NCT02716038 · Phase 2 · registry result, not featured evidence · combination fatigue 65.6% nausea 53.1% dyspnea 51.6% NCT03102242 · Phase 2 · registry result, not featured evidence fatigue 44.1% nausea 27.6% decreased appetite 27% NCT02848651 · Phase 2 · registry result, not featured evidence fatigue 37.7% cough 31.9% dyspnoea 30.4% NCT02031458 · Phase 2 · registry result, not featured evidence fatigue 36.5% cough 32.1% decreased appetite 29.4% NCT02031458 · Phase 2 · registry result, not featured evidence fatigue 38.7% decreased appetite 35.9% cough 31.7% NCT01903993 · Phase 2 · registry result, not featured evidence fatigue 51.6% nausea 35.5% constipation 25.8% NCT01846416 · Phase 2 · registry result, not featured evidence constipation 46.2% fatigue 38.5% diarrhoea 30.8% NCT01846416 · Phase 2 · registry result, not featured evidence · combination fatigue 40.9% cough 35.5% dyspnoea 32.3% NCT01846416 · Phase 2 · registry result, not featured evidence · combination cough 36.4% asthenia 31.8% dyspnoea 29.5% NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination dyspnoea 71.4% hypertension 57.1% asthenia 42.9% NCT03023423 · Phase 1/2 · registry result, not featured evidence · combination | k cough 35.6% (placebo 25.2%) fatigue 24% (placebo 20.1%) dyspnoea 22.3% (placebo 24.4%) NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 32 more resultsdecreased appetite 25.8% constipation 21% cough 17.7% NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 decreased appetite 23.1% diarrhoea 21.4% fatigue 18.8% NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 diarrhoea 20.8% decreased appetite 19.7% asthenia 17.9% NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 anaemia 41.1% (placebo 37%) neutropenia 26.9% (placebo 25.9%) nausea 25.1% (placebo 24.1%) NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 anaemia 45.5% nausea 41.2% neutropenia 29.7% NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 anaemia 44% nausea 34.8% constipation 29.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination anaemia 41.5% nausea 32.7% cough 26.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination hypothyroidism 28.6% (placebo 0%) asthenia 21.4% (placebo 0%) pruritus 21.4% (placebo 0%) NCT04642469 · Phase 3 · registry result, not featured evidence nausea 42.2% (placebo 40.9%) anaemia 33.3% (placebo 27.3%) fatigue 33.3% (placebo 27.3%) NCT04385368 · Phase 3 · registry result, not featured evidence · combination cough 23.4% decreased appetite 13.5% fatigue 13.5% NCT02087423 · Phase 2 · registry result, not featured evidence · combination decreased appetite 26.8% fatigue 26% cough 21.1% NCT02087423 · Phase 2 · registry result, not featured evidence fatigue 29.4% constipation 23.5% cough 19.1% NCT02087423 · Phase 2 · registry result, not featured evidence anaemia 24.5% asthenia 24.5% dyspnoea 20.8% NCT04249362 · Phase 2 · registry result, not featured evidence cough 24.5% constipation 20.4% fatigue 20.4% NCT04249362 · Phase 2 · registry result, not featured evidence weight loss 80% anorexia 70% fatigue 70% NCT04003246 · Phase 2 · registry result, not featured evidence fatigue 68.7% nausea 67.2% diarrhea 62.7% NCT02572843 · Phase 2 · registry result, not featured evidence cough 42.6% asthenia 24.6% pruritus 24.6% NCT03822351 · Phase 2 · registry result, not featured evidence · combination cough 32.2% dyspnoea 25.4% asthenia 18.6% NCT03822351 · Phase 2 · registry result, not featured evidence · combination cough 37.7% asthenia 25.4% dyspnoea 23.7% NCT03693300 · Phase 2 · registry result, not featured evidence asthenia 66.7% cough 66.7% dyspnoea 66.7% NCT03693300 · Phase 2 · registry result, not featured evidence constipation 66.7% fatigue 60% cough 43.3% NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy constipation 70% anemia 53.3% fatigue 46.7% NCT02904954 · Phase 2 · registry result, not featured evidence · combination anemia 63.8% hypoalbuminemia 55.3% lymphocyte count decreased 48.9% NCT02879617 · Phase 2 · registry result, not featured evidence 1500 mg fatigue 23.1% procedural pain 19.2% asthenia 11.5% NCT03794544 · Phase 2 · registry result, not featured evidence 1500 mg + 200 mg dyspnoea 18.8% fatigue 18.8% alanine aminotransferase increased 12.5% NCT03794544 · Phase 2 · registry result, not featured evidence · combination 1500 mg + 750 mg constipation 10% fatigue 10% pruritus 10% NCT03794544 · Phase 2 · registry result, not featured evidence · combination 1500 mg + 3000 mg fatigue 19% asthenia 14.3% cough 14.3% NCT03794544 · Phase 2 · registry result, not featured evidence · combination decreased appetite 34.8% fatigue 34.8% anaemia 30.4% NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination cough 35.3% fatigue 32.4% nausea 32.4% NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation context differs: registered conditions differ.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 2 versus Phase 4.
- fPopulation comparability has not been reviewed for both studies.
- gTreatment context has not been resolved for both arms.
- hAssessment timepoints differ: 6 weeks versus 12 weeks.
- iTrial phases differ: Phase 3 versus Phase 4.
- jPopulation comparability has not been reviewed for 35 of these studies.
- kPopulation comparability has not been reviewed for 29 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Atezolizumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 817 further endpoints in the CSV export.
Durvalumab
show 1 more result
show 3 more results
show 4 more results
show 2 more results
show 2 more results
+ 32 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atezolizumab's landscape · Durvalumab's landscape